dalteparin has been researched along with Mucocutaneous Lymph Node Syndrome in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Mucocutaneous Lymph Node Syndrome: An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 5.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 1.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orbak, Z | 1 |
| Laloglu, F | 1 |
| Akat, H | 1 |
| Inamo, Y | 1 |
| Saito, K | 1 |
| Hasegawa, M | 1 |
| Hayashi, R | 1 |
| Nakamura, T | 1 |
| Abe, O | 1 |
| Ishikawa, T | 1 |
| Yoshino, Y | 1 |
| Hashimoto, K | 1 |
| Fuchigami, T | 1 |
2 other studies available for dalteparin and Mucocutaneous Lymph Node Syndrome
| Article | Year |
|---|---|
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; | 2021 |
Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
Topics: Anticoagulants; Chemotherapy, Adjuvant; Child, Preschool; Coronary Artery Disease; Dalteparin; Femal | 2014 |